Webster served as co-founder, President and Chief Executive Officer for Neuronyx, Inc., a biopharmaceutical company, from 2000 to 2006. Webster previously served in positions of increased responsibility, including as Director, Investment Banking Division, Health Care Group for PaineWebber Incorporated. He also was a co‑founder and served as president and chief executive officer of Neuronyx, Inc. Prior to this, Mr. Webster held positions of increasing responsibility, including as director, Investment Banking Division, Health Care Group, for PaineWebber Incorporated. Neuronyx in Malvern, reviews by real people. Yelp is a fun and easy way to find, recommend and talk about what’s great and not so great in Malvern and beyond.

Executive Summary The time is right to get into the blossoming field of stem cells, believes the high-profile founder of Neuronyx Inc., Hubert Schoemaker, PhD. Fresh from the sale of Centocor, the first-generation biotech that he co-founded, Shoemaker founded Neuronyx in 1999 to develop stem cell-based therapies for neurological disorders. Find 10 listings related to Neuronyx Inc in Malvern on YP.com. See reviews, photos, directions, phone numbers and more for Neuronyx Inc locations in Malvern, PA.

Head of Research and Development

Telecharger Neuronyx

Dr. Tony Ho has served as our Executive Vice President, Research and Development since August 2017. He is a highly accomplished R&D leader with experience throughout his nearly 20-year career across all phases of R&D, including discovery, early and late-stage clinical development and regulatory. Prior to joining our company, Tony held a number of roles at AstraZeneca, most recently Senior Vice President and Head of Oncology Integration and Innovation. At AstraZeneca, he led the development and commercialization of two key drugs: LYNPARZA, a PARP inhibitor for ovarian cancer, and IMFINZI, a PD-L1 inhibitor and AstraZeneca’s first immuno-oncology drug for bladder cancer. Prior to joining AstraZeneca, Tony was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., and led multiple development programs including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma. Prior to joining Merck, Tony was the Co-Founder and Chief Scientific Officer of Neuronyx, a regenerative medicine company. Tony currently serves on the Board of Directors of Engrail Therapeutics. He received his M.D. from the Johns Hopkins University School of Medicine and his B.S. in Electrical Engineering at the University of California, Los Angeles. He completed his residency and neurophysiology fellowship in the Department of Neurology at the Johns Hopkins Hospital. He was an Assistant Professor at Johns Hopkins Hospital and is an adjunct Associate Professor at the University of Pennsylvania and Johns Hopkins University. He has published over 80 papers across several fields and is co-inventor of seven patents.

Neuronex

You are now leaving the CRISPR Therapeutics website.

Neuronyx Inc

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.